Chapters Transcript Video Belimumab Reduces Severe Flares in Systemic Lupus Michelle Petri who is the Director of The Johns Hopkins Lupus Center discusses the impact of severe lupus flares. yeah mm mm. Severe flares of lupus have occurred in about 10% of patients in these clinical trials of sle therapies, a severe flare usually is going to require a hospitalization. A large increase in predniSONE which has long term damage associated with it. And of course to the patient, they're not going to work or go to school or take care of their Children because they're very sick. We have an instrument called the Selena flare index that has been really very good at capturing severe flares in a reliable and reproducible way. Mm hmm. one of the reasons to escalate therapy and to add biologics such as Bolivia map is to prevent severe flares. There is previous knowledge that dilemma math does reduce severe flares in lupus. This new analysis adds to that because it combines all the Bolivia map clinical trials. Having access to a larger database means that it's possible to do subset analyses. One of the ways that we subset lupus are by blood tests that in a way measure the blood activity of lupus. We call these serology ease. It is low compliment and anti DNA. The subset analysis of the Bolivia map trial data show that golimumab particularly reduces severe flares and patients who have these active serology ease. Mm. Yeah. There was an additional finding that I think is quite important for clinicians. We tend to wait and try a lot of other things before we turn to biologics. one instructive finding from this Bolivia map pooled database analysis was that patients who had no organ damage. So there earlier in the course of disease had a reduction in severe flares if they were on Belinda, this does suggest that it is appropriate to add the limb, a mob and other advanced treatments earlier in the disease course, not waiting for the patient to have to already have permanent organ damage, permanent organ damage and lupus is biblical. We always teach that organ damage we get more organ damage and the more the organ damage, the higher the mortality risk. So I think these kinds of studies, which are based on huge data sets, do need to change the way we practice treatment in Sle Yeah. Created by Related Presenters Michelle Petri, MD, MPH Director, Johns Hopkins Lupus Center Professor of Medicine View full profile
Facebook
Twitter
YouTube
LinkedIn
Instagram
E-News
BROADCASTMED